Colinz Laboratories has concluded the sale of its factory undertaking located in Nashik for an aggregate consideration of Rs 4 Cr. The company received the second and final tranche of the payment on June 18, 2026, finalizing the transaction which included the factory building, machinery, and land situated at Plot No 60, STICE, Sinnar-Shirdi Road, Sinnar, Nashik-422112. The sale was executed to M/s. Hilsun Foods And Drugs Private Limited, an unrelated third party, ensuring the transaction was conducted at arm's length and falls outside the scope of a related party transaction.

Transaction Details

The agreement for the sale involved an MOU cum deed of assignment executed on January 26, followed by the Assignment of Leasehold Rights on June 18, 2026. The completion of the sale and disposal was officially recorded on June 18, 2026. The buyer, Hilsun Foods And Drugs Private Limited, holds its registered office at C-103, Rameshwar, Neelkanth Heights, Pokhran Road No. 2, Thane West - 400606, and is not part of the promoter or promoter group of Colinz Laboratories.

Regulatory Disclosures

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that the transaction is outside a Scheme of Arrangement and does not constitute a slump sale. Consequently, specific disclosures regarding amalgamation or merger were not applicable to this disposal of immovable property.

A group of acquirers comprising Annjana Dugar, Likhitta Dugar, and Antariksh Dugar, along with Person Acting in Concert (PAC) Padam Dugar, has initiated an open offer to acquire up to 26% of the voting share capital of Colinz Laboratories Limited . The offer is priced at ₹54 per equity share, representing a total consideration of ₹3,53,68,164, and is being made pursuant to the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The open offer was triggered following the execution of a Share Purchase Agreement dated June 18, 2026, between the acquirers and selling shareholder Vijaya Mani. Under this agreement, the acquirers are purchasing 8,70,500 equity shares, constituting 34.56% of the total voting share capital, at a price of ₹50 per share for a total consideration of ₹4,35,25,000. This transaction will result in the acquirers and the PAC assuming control over the target company and becoming co-promoters.

Saffron Capital Advisors Private Limited has been appointed as the manager to the offer. The acquirers have confirmed they possess adequate financial resources to meet the obligations under the offer and have made firm financial arrangements for the acquisition. The offer is not conditional upon any minimum level of acceptance and is not being issued pursuant to a competitive offer.

Offer and Transaction Details

The open offer targets 6,54,966 fully paid-up equity shares of face value ₹10 each. The acquirers, who are immediate relatives of the PAC, currently hold a combined 15.01% of the voting share capital. Upon completion of the underlying transaction and excluding the open offer shares, their combined holding is set to increase to 49.56%.

Target Company and Selling Shareholder

Colinz Laboratories Limited is listed on BSE Limited with a scrip code of 531210. The selling shareholder, Vijaya Mani, is part of the promoter group and currently holds 34.56% of the voting share capital. Following the consummation of the underlying transaction, Vijaya Mani will cease to hold any equity shares and will be reclassified from the promoter to the public category.

The acquirers have stated they have no intention to delist the equity shares of the target company pursuant to this open offer. A Detailed Public Statement is expected to be published on or before June 25, 2026.